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Cerfolio RJ, Bryant AS, Ojha B. Restaging patients with N2 (stage IIIa) non–small cell lung cancer
after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg. 2006;131:
1229-35.
Due to an administrative error, the Discussion for the above article was not published in the June
2006 issue. It is printed herewith.N
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r R. Korst (New York, New York): I have the privilege of
eginning this discussion, and I congratulate Dr. Cerfolio
nd his colleagues at Birmingham on really another signif-
cant contribution regarding PET scanning and thoracic
alignancies.
Using a prospective series of nearly 100 patients with N2
isease who underwent neoadjuvant chemoradiotherapy
rior to surgical resection, these investigators acquired and
re reporting upon an impressive dataset regarding the ac-
uracy of CT/PET in restaging the mediastinum after com-
letion of induction therapy. Of additional significance, and
e discussed this a little bit earlier, is that all PET scans
ere performed using the same scanner and the same scan-
ing regimen, essentially eliminating the potentially con-
ounding effect of interscanner variation. This focus on
ost-induction restaging implies that therapeutic decisions
ill be made on the restaging results. As an example of this,
r. Cerfolio’s algorithm calls for patients with residual
ediastinal disease after neoadjuvant chemoradiotherapy to
e referred back to the oncologist without an attempt at
urgical resection. The issue of persistent N2 disease after
nduction therapy, however, is extremely controversial.
ome retrospective series have suggested that patients with
esidual N2 disease after induction therapy have a negligible
ure rate after surgical resection; however, other reports,
ncluding a single report from our own institution, have
hown 5-year survival rates approximating 20% for this
ohort of patients who undergo surgery. In addition, data
rom the surgical arm of the North American Intergroup
139 randomized trial have demonstrated that patients with
esidual mediastinal disease after neoadjuvant chemoradia-
ion have a 5-year survival rate of 24% when resection is
erformed. In summary, although a complete pathologic
esponse in the mediastinum is ideal, it seems clear that
ome patients with residual N2 disease benefit from surgery.
Given this information, I have essentially only two ques-
ions. First, what treatment do you offer patients with residual
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The Journal of Thoracic2 disease after induction therapy if you do not offer surgical
esection, and what is the survival rate in this cohort? Are the
esults of alternative treatments as good as the nearly 25% cure
ate seen in the intergroup trial, especially given the interrup-
ion in radiation therapy that must occur during the restaging
rocess. Second, even if decisions will be made on post-
nduction restaging results, given the significant false-positive
nd false-negative rates of CT/PET that you mentioned after
eoadjuvant chemoradiation, do you continue to advocate the
erformance of this examination in the post-induction setting?
I want to thank Dr. Cerfolio for forwarding me the
anuscript ahead of time and the Association for the priv-
lege of discussing it.
Dr Cerfolio. Dr. Korst, those are great questions, thank
ou. The reason that we use a neoadjuvant chemoradiother-
py dose of 63 Gy or 66 Gy is so that there is no interruption
etween our neoadjuvant therapy and definitive therapy.
bout 5 or 6 years ago we made the cognitive leap to use
igher doses of chemoradiotherapy so that we would not
ffect the efficacy of the patient’s radiotherapy. He has
lready received “curative doses of chemoradiotherapy,” so
f he does not go on to resection you have at least maxi-
ized his medical therapy. Once he completes his radiation,
ou wait 4 weeks and rePET and re-CT him. Then you do
mediastinoscopy or a repeat EUS, and if he has residual
2 I usually do not resect the patient, but rather send him
ack for more or different chemotherapy and then reassess
is N2 disease again. Once N2 negative, I will consider
esection. Some selected patients—-those who are young,
ave excellent PFTs, have minimal operative risk, and who
an have all disease resected without the need for a pneu-
onectomy---I may resect with known residual or recalci-
rant N2, but that is not my usual practice.
The second part of the first question is what is the
urvival of these patients. We all know that N2 patients are
heterogeneous group. So I can look at patients who have
icroscopic N2 disease and tell you their survival is quite
ood, maybe 40 or even 50%, but I can also evaluate
atients with bulky recalcitrant N2 disease and tell you that
ven with resection their survival is poor, probably 10%.
ou and I know that that’s not really a surgical disease, and
hey don’t do well with surgical resection. So it comes down
o really patient selection to answer that question.
and Cardiovascular Surgery ● Volume 132, Number 3 565
p
b
a
t
h
t
i
h
m
o
n
s
s
a
c
R
y
c
o
s
t
y
l
a
w
a
t
a
P
p
y
t
y
c
y
E
f
c
a
q
p
w
a
a
d
l
t
s
r
h
i
o
N
a
d
r
h
u
l
h
p
o
P
u
t
a
P
H
t
m
c
a
d
d
w
c
y
c
t
o
c
u
b
u
a
w
c
v
a
s
m
r
s
t
Notice of Correction
5Finally, your third point, do I recommend PET for these
atients? In short, I absolutely do. So much information can
e gleaned off the PET if we as surgeons just carefully look
t it and if the nuclear radiologists provide us with reports
hat help us. At UAB our integrated FDG-PET/CT reports
ave the maxSUV of each lymph node that’s greater than
he background, each lymph node is labeled with a number,
e, 2R or 4R, etc., the repeat and initial scan are both done
ere ideally, and the percent change of the primary tumor’s
axSUV and of each node is calculated. This provides
utstanding biological information as to the efficacy of the
eoadjuvant therapy, and that is what I want to know as a
urgeon who is contemplating resection for patients with N2
tage IIIa lung cancer. Do they have favorable or unfavor-
ble disease? Thank you.
Dr Mark J. Krasna (Baltimore, Maryland). I want to
ompliment Dr. Cerfolio on another excellent presentation.
ob, like Dr. Sonett’s group, Dr. Daly’s group, and our own,
ou have been embracing high-dose chemoradiation as well as
areful surgical staging, and I really laud you for that. On the
ther hand, I must make two comments. Number one, I’m
urprised at your low complete pathologic response rate given
hat you use very high-dose chemorads, and I really wonder if
ou could comment. Just grabbing it off your slide, it looked
ike it was about a 17% path CR rate, which is way lower than,
s we had discussed among several of our groups in the past,
e have seen in larger groups. So if you can comment on that.
My question relates to what Dr. Korst was alluding to,
lso. If you are going to use the PET/CT, one alternative
hat has actually been recommended by the Germans at
ctually this meeting a year or so ago is to use the repeat
ET/CT early in the therapy as a way of determining if the
atient is responding or not and perhaps adjusting either
our schedule or your dose based on that information. So
he question, then, is if you can’t use the PET/CT where
ou’re using it with better accuracy, and, like Dr. Korst, I’m
oncerned about those false-negatives and -positives, and
ou yourself have such an excellent tradition of TBNA and
US-FNA, why not EUS-FNA and TBNA everybody up
ront and then do a mediastinoscopy on everybody after the
hemorads?
I enjoyed your paper.
Dr Cerfolio. Well, your third question has gotten into
nother study that we have completed, so I’ll answer that
uickly. At the 2006 Western in Idaho this year we’ll be
resenting exactly that---a prospective study of patients
ith integrated PET/CT and CT scan N2 negative. We did
n upfront EUS-FNA and mediastinoscopy on all of them,
nd it was rarely positive unless they had suspicion of N1
isease, a maxSUV of the primary of 10 or greater, or upper
obe adenocarcinoma. So I cannot recommend those two
ests up front unless N2 disease is implicated. If N2 is
uggested, it makes sense to reserve the med for after the S
66 The Journal of Thoracic and Cardiovascular Surgery ● Septeadiotherapy if you can prove the N2 by EUS-FNA. This
as been a strategy we and others have done for many years
n our patients with Pancoast, but this has the disadvantage
f missing occult N3 disease (EUS-FNA does not really find
3). This is uncommon for Pancoast but not for bulky N2,
nd knowing that before the adjuvant therapy makes a
ifference in your treatment algorithm.
Your first question was about why the low complete
esponse rate. I think it has to do with your pathologist and
ow diligently he or she examines the final specimen. We
sed a very strict definition of no viable tumor before we
abeled it CR. You and I have talked about this before. If we
ad accepted a few viable cells and called it a CR, our
ercentage rate would have been much higher. We had a lot
f T1’s that you may have called complete responders.
Finally, your second question, what about using a repeat
ET during the therapy, I caution you not to use that if you’re
sing neoadjuvant radiotherapy with the chemo as we did in
his manuscript. If the patient only has induction chemother-
py, we do exactly as you suggest, we use interval integrated
ET to look at efficacy or effectiveness of chemotherapy.
owever, here we are using induction chemoradiotherapy, and
hat is quite different. It is difficult to reinterpret a PET in the
iddle of radiotherapy, so I caution you on that. We are
urrently studying our data, via ROC curves, to find the most
ccurate time to re-PET a patient after neoadjuvant chemora-
iotherapy, and we believe it is about 5 to 8 weeks after the last
ose of radiation.
Dr Claude Deschamps (Rochester, Minn). Cerf, that
as a great paper. Thank you very much. I have one
omment and one question. I wonder if you had a typo in
our first slide, the introduction, when you said standard of
are is chemoradiation and maybe surgery. Are you aware
hat some of us don’t give chemo to some of those patients
r don’t give radiation, especially radiation? Maybe you can
omment on that comment.
My question is, when you restage those patients, do you
se redo mediastinoscopy, endobronchial ultrasound of the
ronchus? Do you use transesophageal ultrasound? Do you
se Wang biopsy?
Dr Cerfolio. Thank you very much, Dr. Deschamps, I
ppreciate your question, especially as one of my teachers
hen I was at Mayo. No one travels more than you, sir, so
ertainly it’s not from my travels. I agree that it is contro-
ersial and I actually put that up there intentionally, it is not
typo. I thought we left it up there to be intriguing. It is my
tandard of care in my practice for N2 disease, and I think
ost surgeons have moved or are moving to it instead of
esection alone or chemotherapy alone. But it is not unrea-
onable to use induction chemotherapy. Some might argue
hat for microscopic N2 disease it’s reasonable just to resect.
o I think, again, it depends on your point of view and the
mber 2006
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as in there intentionally.
Your second question, how do we restage these patients, I
o not do repeat mediastinoscopy. First of all, I think it is
otentially dangerous. We haven’t had any bleeding yet or
ortalities, but it’s harder to do, and you’re a little more
ervous doing a repeat mediastinoscopy after 65 Gy of radia-
ion than you are doing a sleeve lobectomy, in my opinion. But
ore importantly is that I don’t think it’s accurate, that is the
ig point. So we use repeat EUS, and more recently we’re
bout to launch a prospective study looking at repeat EBUS,
hich I think will be very good, although I’m not sure about
he N2. It’s really more for N1. We don’t use repeat Wang
ecause I think repeat Wang has been replaced by repeat
US—one actually sees where the needle is going.
Dr Timothy Anderson (Boston, Mass). Cerf, I enjoyed
our paper. I didn’t hear a word about the Chamberlain n
The Journal of Thoracicrocedure in level 5, level 6. That may be a somewhat
rivileged area with a better prognosis, maybe somebody you
ight go on to resection with. How do you tackle that area?
Dr Cerfolio. Actually, I just worked on an abstract for a
eeting in hopefully a few months on that. I don’t do
hamberlain anymore, I do repeat VATS for number 5 and
umber 6. So we’re looking at the accuracy of getting to 5
nd 6 and finding that EUS-FNA doesn’t get there very
ccurately. I don’t do extended mediastinoscopy, as some of
ou may do. So I’m left with repeat VATS, and we’re
nding in these data that we just looked at that a VATS is
he best way in my hands to get to the 5 or the 6. There’s
sually a large tumor, so it’s hard to get there with Cham-
erlain. So VATS has supplanted Chamberlain for that
umber 5 and that number 6 area that we’re finding out in
ur data is really EUS-FNA blind; the EUS gets to the 4L,
ot the 5.
and Cardiovascular Surgery ● Volume 132, Number 3 567
